PAH Space Getting Hotter as Actelion Files Macitentan NDA

LONDON – There's a race to market for a new generation of pulmonary arterial hypertension (PAH) drugs with Actelion Ltd. announcing it has filed for FDA approval of Opsumit (macitentan) and Bayer Healthcare revealing positive Phase III data for riociguat and promising global filings in the first half of 2013.